Perverse Incentives — HIV Prevention and the 340B Drug Pricing Program-Reference-Cited by-同舟云学术

Perverse Incentives — HIV Prevention and the 340B Drug Pricing Program

Published:2022-06-02 Issue:22 Volume:386 Page:2064-2066
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Marcus Julia L.¹^ORCID,Killelea Amy¹,Krakower Douglas S.¹

Affiliation:

1. From the Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute (J.L.M., D.S.K.), and the Division of Infectious Diseases, Beth Israel Deaconess Medical Center (D.S.K.) — both in Boston; and Killelea Consulting, Arlington, VA (A.K.).

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMp2200601

Reference2 articles.

1. Comparative Pricing of Branded Tenofovir Alafenamide–Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate–Emtricitabine for HIV Preexposure Prophylaxis

2. Why Are Patients Switching from Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) to Tenofovir Alafenamide/Emtricitabine (Descovy) for Pre-Exposure Prophylaxis?

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trends in HIV preexposure prophylaxis utilization and spending among individuals with commercial insurance;AIDS;2024-02-29

2. Life-Saving Treatments for Spinal Muscular Atrophy;Neurology Clinical Practice;2024-02

3. Preexposure Prophylaxis to Eliminate HIV in Taiwan by 2030: A Modeling Study;2023-10-06

4. 340B—Where Do We Go From Here?;JAMA;2023-08-15

5. HIV Pre-Exposure Prophylaxis in the Emergency Department: A Systematic Review;Annals of Emergency Medicine;2023-04